&w=3840&q=100)
Glenmark hits new high; zooms 37% in 2 months; what's driving pharma stock?
Glenmark Pharmaceuticals share price
Shares of Glenmark Pharmaceuticals hit a new high of ₹1,886.40, as they rallied 4 per cent on the BSE in Thursday's intra-day trade in an otherwise weak market. In comparison, the BSE Sensex was down 0.36 per cent at 83,230 at 11:39 AM.
Since June 25, in the past 12 trading days, the stock price of the pharmaceutical company has surged 12 per cent after the company launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. In the past two months, the stock price of Glenmark has zoomed 37 per cent.
What's driving Glenmark stock price?
Glenmark Pharmaceuticals on June 24 said it launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation (CDSCO).
Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers which are difficult to treat, the company said in a regulatory filing.
Glenmark on June 18 said that the United States Food & Drug Administration (USFDA) conducted a GMP inspection at the company's manufacturing facility situated in Monroe, North Carolina, US from 09 June 2025 to 17 June 2025.
At the end of the inspection, the company was issued a Form 483 with five (5) observations. All the observations are procedural in nature. There was no observation related to data integrity reported. The company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline, Glenmark said.
Brokerages view on Glenmark
While the January-March quarter (Q4FY25) performance was weak - impacted by delayed product launches, a subdued respiratory season, and compliance-related costs at the Monroe facility - analysts at Choice Equity Broking believe Glenmark is well-positioned for a rebound.
Growth is expected to be driven by a robust pipeline in respiratory and injectable segments across existing markets, along with the expansion of key global brands into new geographies. Management has guided for 10 - 12 per cent revenue growth in FY26. Furthermore, enhanced in-house manufacturing and cost optimization at Ichnos Glenmark Innovation (IGI) are likely to support EBITDA margin improvement. However, currently, the stock trades above the brokerage firm's target price of ₹1,670 per share.
According to Motilal Oswal Financial Services, on the innovation front, the potential for ISB2001 continues to improve with fast-track designation for relapsed/refractory Multiple Myeloma (MM). Glenmark delivered considerable margin expansion (780bp YoY) in FY25, aided by healthy growth in the European business and a reduction in R&D spending.
Glenmark strengthened its differentiated offerings in the US generics segment with products like g-Flovent. With the gradual recovery in domestic formulations and superior execution in the EU/ROW markets, the brokerage firm expects 11 per cent/18 per cent/24 per cent sales/EBITDA/ PAT over FY25-27.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
43 minutes ago
- Mint
Best stock recommendations today: MarketSmith India's top picks for 20 August
Indian equity benchmarks delivered a fourth consecutive session of gains, with BSE Sensex closing approximately 370 points higher, while Nifty50 ended just below 25,000, crossing 24,950. Optimism stemmed from strong performances by Reliance Industries and Bharti Airtel, which helped fuel the rally. The market's positive momentum was largely fueled by sustained foreign institutional investor (FII) buying and lingering optimism from last week's GST rationalization discussions. Two stock recommendations by MarketSmith India for 20 August: Buy: L&T Finance Holdings(current price: ₹ 217) Buy: Asahi India Glass Limited (current price: ₹870) Nifty 50 recap On Tuesday, Indian benchmark indices extended their rally, with both Nifty 50 and Sensex closing in the green for the fourth consecutive session. After a muted opening, the market extended its bullish momentum from the previous session and ended just below 25,000. The broader market outperformed the frontliners, with the BSE Midcap and Smallcap indices gaining around 1% each. On the sectoral front, oil and gas, media, and auto stocks led the gain, while pharma was the sole laggard. Notable stock movers included Tata Motors, Adani Ports, and Reliance Industries among the top gainers, while Dr. Reddy's Labs and Cipla were among the day's biggest losers. The overall market breadth was highly positive, with a strong advance-decline ratio, suggesting broad-based buying interest across the board. On the technical front, Nifty encountered resistance at its 50-DMA, which remains a key hurdle for further upside. The relative strength index (RSI) has recovered from oversold territory and recently broke above a downward-sloping trendline, now consolidating near the neutral 55 level—indicating improving momentum. Meanwhile, the MACD has turned positive, though it continues to trade below both its signal line and the zero axis, suggesting that while downside pressures have eased, a sustained confirmation of trend reversal is still awaited. According to O'Neil's methodology market direction, market status has been downgraded to an "Uptrend Under Pressure" as Nifty breached its "50-DMA" and the "distribution day count" is at four. The index continues to encounter strong resistance near its 50-DMA, with 25,000 and the 50-DMA is likely to remain the key resistance zone in the near term. A decisive close above this hurdle would be a constructive technical development and could open the path for an upside move toward 25,250–25,350. On the downside, immediate support is placed at 24,700, where a breach could negate the current recovery attempt and reintroduce selling pressure. Below this, further supports are seen at 24,600 and 24,350, making these critical levels to watch for the index's next directional move. How did Nifty Bank Perform Yesterday? On Tuesday, Bank Nifty began on a weak note and witnessed volatile movement in the early hours of trade. However, buying interest at lower levels provided positive momentum, helping the index close in the green. It formed a bullish candle, signaling strength, though it faced resistance near its 21-DMA, placed at 25,911. Throughout the session, it opened at 55,622.30 and moved within a narrow range of 55,965.55 to 55,608.15. Eventually, it closed at 55,865.15, sustaining its intraday gains. The price action reflects resilience, though a breakout above the 21-DMA will be crucial for further upside. The RSI has inched higher from the previous session and is now positioned near 50, indicating improving momentum. Meanwhile, the MACD has turned positive after several weeks of a negative crossover, though it continues to trend below the central line, signaling caution. According to O'Neil's methodology market direction, Bank Nifty remains in an 'Uptrend Under Pressure." In this context, investors should maintain a selective exposure to quality stocks while emphasizing disciplined risk management to safeguard capital and capture only high-conviction opportunities. Bank Nifty closed the session in positive territory but faced resistance near its 21-DMA. A sustained move above this level could open the path toward the next hurdle at the 50-DMA, placed around 56,330. For bullish momentum to strengthen, the index must decisively cross and hold above the 50-DMA in the coming sessions. On the downside, immediate support lies at the 100-DMA near 55,239. A breach below this level may trigger heightened volatility and increase the risk of further downside. MarketSmith India is a stock research platform and advisory service focused on the Indian stock market. It offers tools and resources to help investors make informed decisions based on the CAN SLIM methodology, founded by legendary investor William J. O'Neil. You can access a 10-day free trial by registering on its website. Trade name: William O'Neil India Pvt. Ltd. Sebi Registration No.: INH000015543 Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
5 hours ago
- Economic Times
Inox Wind sells Rs 175 cr stake in EPC subsidiary at ₹7,400 cr valuation
Wind energy solutions provider, Inox Wind (IWL), on Tuesday said it has sold a stake worth ₹175 crore in its EPC subsidiary, Inox Renewable Solutions (formerly Resco Global Wind Services), to investors at a valuation of ₹7,400 crore. The company did not disclose who these investors are. This latest development comes after the National Company Law Tribunal approved the merger of Inox Wind Energy (IWEL) into IWL on June 10, 2025, strengthening the company's balance sheet by reducing liabilities by about ₹2,050 crore. Last September, Inox Renewable Solutions had approved a ₹350 crore equity raise from investors for a single-digit stake. Inox Renewable Solutions offers end-to-end services for wind projects right from the conceptualisation stage up to project commissioning, as well as the construction of transmission infrastructure to evacuate power from such projects, offering turnkey solutions to developers on a plug-and-play basis. It provides services across India with a strong presence in Western India. It is developing common infrastructure on the multi-gigawatt scale at sites across the country, to be utilised for future renewable projects. Inox Wind's scrip ended at ₹144.40 up 3.18% on the BSE, Tuesday.
Time of India
6 hours ago
- Time of India
Expansion plans & easing asset woes to lift CreditAccess
ET Intelligence Group: The stock of CreditAccess Grameen has gained nearly 12% over the past eight trading sessions after the country's largest microfinance lender announced the appointment of Ganesh Narayanan as the new managing director and CEO on August 6 after RBI's approval. The sector indices have gained over 1% during the period. The company has undertaken accelerated write-offs to clean up the loan book , which has resulted in higher credit costs. The situation is expected to normalise from the December quarter. Given the company's plan to open 200 branches in the current fiscal year and receding pressure on asset quality , the credit growth is expected to be higher in the second half of the current fiscal year. Dwindling credit quality in the microfinance segment over the past few quarters has affected the performance of CreditAccess. For its overall portfolio, 90-day PAR (portfolio at risk ratio) shot up to 3.3% from 1.1% in the year-ago quarter. The company has suffered a greater asset quality stress in Karnataka, which accounts for nearly one-third of its loan book. The PAR ratio for Karnataka in the 90 days and above category increased to 5.1% in the June quarter from 2.4% in the previous quarter. Live Events According to the company management, Karnataka has started showing stabilisation in PAR in the current quarter. In addition, the implementation of stricter norms for loan disbursement has reduced the proportion of highly leveraged borrowers (which have borrowed from three or more lenders) to 11.4% in June from 25.3% last August. The credit cost increased to ₹571.9 crore in the June quarter from ₹420.1 crore in the September 2024 quarter. This was largely due to accelerated write-offs as the proportion of new PAR accretion in the credit cost fell to 61% from 90% during the period. This raises hope that credit costs may ease in the second half of the current fiscal year. Apart from asset cleanup, the company has also increased focus on retail financing, which is likely to form 12-15% of the loan book by FY28. The segment contributed 7% to the gross loans in the June quarter compared with 3% in the year-ago quarter. Axis Securities expects annual growth in loan book and net profit at 18% and over 50% between FY25 and FY28. It has raised target price to ₹1,485 from earlier ₹1,350, implying FY27 expected price-book multiple of 2.5. Stock was last traded at ₹1,351 on Tuesday on the BSE.
